138 related articles for article (PubMed ID: 10351190)
1. Pharmacoeconomic considerations in treating patients with acute leukaemia.
Jønsson V; Hansen MM; Ljungman P; Kaasa S
Pharmacoeconomics; 1999 Feb; 15(2):167-78. PubMed ID: 10351190
[TBL] [Abstract][Full Text] [Related]
2. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
3. Pharmacoeconomic aspects in the treatment of curable and incurable cancer.
Jønsson V; Clausen SR; Hansen MM
Pharmacoeconomics; 1995 Oct; 8(4):275-81. PubMed ID: 10155669
[TBL] [Abstract][Full Text] [Related]
4. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
5. Idarubicin: a pharmacoeconomic evaluation of its use in adult patients with acute myeloid leukaemia.
Whittington R; Goa KL
Pharmacoeconomics; 1993 Oct; 4(4):287-307. PubMed ID: 10146918
[TBL] [Abstract][Full Text] [Related]
6. Cost analysis of 2 empiric antibacterial regimens containing glycopeptides for the treatment of febrile neutropenia in patients with acute leukaemia.
Bucaneve G; Menichetti F; Del Favero A
Pharmacoeconomics; 1999 Jan; 15(1):85-95. PubMed ID: 10345160
[TBL] [Abstract][Full Text] [Related]
7. Treatment cost development of patients undergoing remission induction chemotherapy: a pharmacoeconomic analysis before and after introduction of posaconazole prophylaxis.
Heimann SM; Cornely OA; Vehreschild MJ; Glossmann J; Kochanek M; Kreuzer KA; Hallek M; Vehreschild JJ
Mycoses; 2014 Feb; 57(2):90-7. PubMed ID: 23790060
[TBL] [Abstract][Full Text] [Related]
8. Economic and quality of life outcomes: the four-step pharmacoeconomic research model.
Arikian SR; Suver J; Einarson T; Doyle J
Oncology (Williston Park); 1995 Nov; 9(11 Suppl):33-6. PubMed ID: 8608054
[TBL] [Abstract][Full Text] [Related]
9. [Methodology of pharmacoeconomic studies in oncology].
Ballatori E
Recenti Prog Med; 2008 Jan; 99(1):42-7. PubMed ID: 18389873
[TBL] [Abstract][Full Text] [Related]
10. Propofol. A pharmacoeconomic appraisal of its use in day case surgery.
Fulton B; Goa KL
Pharmacoeconomics; 1996 Feb; 9(2):168-78. PubMed ID: 10172697
[TBL] [Abstract][Full Text] [Related]
11. Paclitaxel: a pharmacoeconomic review of its use in the treatment of ovarian cancer.
Young M; Plosker GL
Pharmacoeconomics; 2001; 19(12):1227-59. PubMed ID: 11772158
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer.
Plosker GL; Hurst M
Pharmacoeconomics; 2001; 19(11):1111-34. PubMed ID: 11735678
[TBL] [Abstract][Full Text] [Related]
13. Cefotaxime. A pharmacoeconomic review of its use in the treatment of infections.
Plosker GL; Foster RH; Benfield P
Pharmacoeconomics; 1998 Jan; 13(1 Pt 1):91-106. PubMed ID: 10175990
[TBL] [Abstract][Full Text] [Related]
14. Health economic impact of high-dose versus standard-dose cytarabine induction chemotherapy for acute myeloid leukaemia.
Fedele PL; Avery S; Patil S; Spencer A; Haas M; Wei A
Intern Med J; 2014 Aug; 44(8):757-63. PubMed ID: 24863325
[TBL] [Abstract][Full Text] [Related]
15. Sumatriptan. A pharmacoeconomic review of its use in migraine.
Coukell AJ; Lamb HM
Pharmacoeconomics; 1997 May; 11(5):473-90. PubMed ID: 10168035
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of topiramate in migraine prevention: results from a pharmacoeconomic model of topiramate treatment.
Brown JS; Papadopoulos G; Neumann PJ; Friedman M; Miller JD; Menzin J
Headache; 2005 Sep; 45(8):1012-22. PubMed ID: 16109115
[TBL] [Abstract][Full Text] [Related]
17. Economic aspects of antibacterial adverse effects.
Beringer PM; Wong-Beringer A; Rho JP
Pharmacoeconomics; 1998 Jan; 13(1 Pt 1):35-49. PubMed ID: 10175984
[TBL] [Abstract][Full Text] [Related]
18. Torasemide: a pharmacoeconomic review of its use in chronic heart failure.
Young M; Plosker GL
Pharmacoeconomics; 2001; 19(6):679-703. PubMed ID: 11456215
[TBL] [Abstract][Full Text] [Related]
19. Next-generation multiple myeloma treatment: a pharmacoeconomic perspective.
Rajkumar SV; Harousseau JL
Blood; 2016 Dec; 128(24):2757-2764. PubMed ID: 27742709
[TBL] [Abstract][Full Text] [Related]
20. Escitalopram: a pharmacoeconomic review of its use in depression.
Croom KF; Plosker GL
Pharmacoeconomics; 2003; 21(16):1185-209. PubMed ID: 14594439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
